fda warning letters compounded semaglutide october 2025 GLP-1s: Why doctors worry and the is cracking down US FDA warns online vendors

If youve spent any time researching semaglutide, tirzepatide, or retatrutide, youve probably come across the word agonist more times than you can count

[9] [10] In individuals with compromised cardiac function, this mechanism may pose additional considerations that require specialist evaluation

Assess risk stratification of member population

Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)

doi: 10.1007/s12020-019-02055-z 93 PintoLCFalcettaMRRadosDVLeitaoCBGrossJL

The drugs novelty lies in the fact that it includes a glucagon receptor agonist, which most other GLP-1 therapies do not have